Effectiveness of the Use of the Human Recombinant Epidermal Growth Factor in the Subsidized Regime vs The Contributive Regime in Patients with Venous Ulcers in Bogotá

DOI: https://doi.org/10.2147/dddt.s437105

IF: 4.3188

2024-05-30

Drug Design Development and Therapy

Abstract:Maria Teresa Cacua Sanchez, 1 Gustavo Buenahora, 2 Carlos Alberto Carrillo Bravo 3 1 Ambulatory Surgery Center, Kennedy Hospital, Vascular Laboratory SURA, Bogotá, Colombia; 2 Hospital and Ambulatory Surgery Center, Bogotá, Colombia; 3 Clinical Epidemiology - Colombian Society of Preventive Medicine, Bogotá, Colombia Correspondence: Maria Teresa Cacua Sanchez, Tel +57-1-3057470125, Email Introduction: Vascular ulcers constitute a serious global public health problem, responsible for causing a significant social and economic impact due to their recurrent, disabling nature and the need for prolonged therapies to cure them. Objective: To evaluate the use and efficacy of the rhEGF in the epithelialization of patients with a diagnosis of CEAP stage 6 venous insufficiency, in the two regimes of the health system in Colombia, the contributive (equivalent to a health system where citizens with payment capacity contribute a percentage of their salary) and the subsidized (equivalent to a health system where the state covers the vulnerable population and low socioeconomic level) versus the other treatments used. Methodology: Observational, descriptive, retrospective, multicenter study, in which 105 medical records with 139 ulcers were reviewed, in 2 centers, one belonging to the subsidized system and the other to the contributive system in Colombia. Results: The association with the epithelialization variable of the different treatment groups for ulcers according to the application of the mixed effect model test, for both regimes was for the Biologicals (EC 34.401/p = 0.000), Bioactive Agents (Hydrogels) (EC 24.735/p = 0.005) groups; for the rest of the treatment groups, the results were neither associated nor statistically significant. Conclusion: Intra- and perilesional therapy with rhEGF expands the therapeutic spectrum in patients with venous ulcers, regardless of the type of health system in which it will be applied, shortening the healing time and reaching a possible therapeutic goal, which according to this study there is an association with epithelialization regardless of the regime applied. Keywords: venous ulcers, human recombinant epidermal growth factor, health system, contributive regime, subsidized regime, intralesional and perilesional Venous vascular ulcers are a pathology difficult to treat. They are a serious public health problem with major health and socio-economic repercussions, venous ulcers are the most common type of chronic ulcers on the lower extremities, and their prevalence is between 1% and 3% if active and cured ulcers are considered. 1 The prevalence of active venous ulcer alone ranges between 0.2% and 0.3% in the adult population of Western countries. 2 On average, 33–60% of these ulcers persist for more than 1 year. 3 Venous ulcers are usually recurrent and generate high costs in their treatment, which directly impacts annual health care budgets. Furthermore, in most cases this type of ulcers occur in patients with a low socioeconomic and educational level. 4 The current standard of care for venous ulcers implies the use of compression bandages to counter venous hypertension. However, these approaches only cure 50–60% of venous ulcers within 6 months of treatment. 5 Nevertheless, with the acquired knowledge about the proteomic physiology that causes this complication, local adjuvant treatments have been developed such as biologic dressings and biomolecular engineering products such as growth factors and therapies with tissues. These products interact directly with the wound to accelerate the healing process and reduce the time to complete its cure. 6 Epidermal growth factors (EGF) are endogenous signaling molecules that regulate cellular responses to the wound healing process, which are secreted by platelets, leukocytes, fibroblasts and epithelial cells, 7 when there is an imbalance between pro- and anti-inflammatory cytokines, wounds tend to become chronic, remaining in an uncontrolled and persistent inflammatory phase, 8 the (EGF) exerts a specific function that results in the regulation of metabolism, differentiation, growth, proliferation and cell survival, 9 thus stimulating the migration and proliferation of fibroblasts, suggesting a useful therapeutic strategy for wound healing, 10 genetic recombination allows recombinant human Epidermal Growth Factor (rhEGF) to be available in pure, precise and stable concentrations as a drug in 75 mg vials for intra- and perilesional administration, 11 with a theoretical basis for its use as a promoter of the healing of wounds such as venous ulcers, which due to its hig -Abstract Truncated-

pharmacology & pharmacy,chemistry, medicinal